Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Abbott's COVID-19 antigen test may help with faster detection, isolation: CDC

Published 01/19/2021, 02:08 PM
Updated 01/19/2021, 02:10 PM
© Reuters. FILE PHOTO:  A general view of Centers for Disease Control and Prevention (CDC) headquarters in Atlanta

By Vishwadha Chander

(Reuters) - Abbott Laboratories (NYSE:ABT)' rapid COVID-19 antigen test is highly likely to correctly detect if people have ever contracted the virus and could help with earlier isolation, according to the U.S. Centers for Disease Control and Prevention.

The test was less sensitive in detecting asymptomatic infection, but the CDC study found that the faster turnaround time can help limit transmission by more rapidly identifying infectious persons for isolation. (https://

The study comes when public health departments are scrambling to implement strategies to reduce or prevent the rapid spread of the virus, with the United States recording more than 200,000 new cases and 3,220 deaths on average over the last seven days.

Several rapid antigen tests have been approved by the U.S. Food and Drug Administration for emergency use, but data lacks on test performance in asymptomatic people, according to a team of scientists from CDC's COVID-19 Response Team and the Arizona Department of Health Services.

Using the real-time reverse transcription–polymerase chain reaction, or RT-PCR, test as the standard, the CDC studied over 3,400 specimens collected from people aged over 10 years at two community testing sites in Pima County, Arizona, from Nov. 3 to Nov. 17.

Compared with RT-PCR, Abbott's BinaxNOW antigen test had a sensitivity of 64.2% for specimens from symptomatic people and only 35.8% for specimens from asymptomatic people.

It had near 100% specificity in specimens from both groups, suggesting very few false positives and no false negatives.

"BinaxNOW is great at finding infectious people – and this Pima County study demonstrates that BinaxNOW is 92.6% effective at identifying positive cases when people are infectious - in line with our performance data," Abbott said in an emailed statement.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The researchers said swabs from the back of the nose were taken for the RT-PCR tests, which might have contributed to increased detection for the real-time RT-PCR assay. Swabs from the front of the nose were used for BinaxNOW.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.